Tim Heffernan

179 posts

Tim Heffernan

Tim Heffernan

@timheff5

Katılım Kasım 2016
330 Takip Edilen386 Takipçiler
Tim Heffernan retweetledi
UT MD Anderson
UT MD Anderson@UTMDAnderson·
That's a wrap on #ASCO26. This year, UT MD Anderson shared nearly 130 abstracts, including 34 podium presentations, advancing research and bringing new insights to cancer care. Thank you to everyone who connected with us at our booth, attended presentations and joined the conversation throughout the meeting. @ASCO #EndCancer
UT MD Anderson tweet mediaUT MD Anderson tweet mediaUT MD Anderson tweet mediaUT MD Anderson tweet media
English
0
9
48
2.5K
Albert Koong, MD PhD
Albert Koong, MD PhD@ACKoongMDPhD·
Any guesses regarding where is this location?
Albert Koong, MD PhD tweet media
English
8
0
20
4K
Tim Heffernan retweetledi
Kate McAndrews
Kate McAndrews@mcandrews_kate·
Excited to share our collaborative paper with @Aiims1742 @timheff5 @rkalluriMDPhD @Boehringer @IamLinghua @cjder23 and @broadinstitute PRISM lab describing the efficacy of BI-2493 (panKRASi) in preclinical PDAC models. 🧵1/4
Anirban Maitra@Aiims1742

Congratulations to @mcandrews_kate @MDAndersonNews for @ScienceTM paper, a collaboration @Boehringer @timheff5 @rkalluriMDPhD An allele-agnostic mutant-KRAS inhibitor suppresses tumor maintenance signals and reprograms tumor immunity in #PancreaticCancer science.org/doi/10.1126/sc…

English
2
7
29
4.9K
Hussein Abbas
Hussein Abbas@HusseinAbbasLab·
DOD grant on TP53 AML was awarded!! Back to my graduate school roots. Important to realize that i had 7 unfunded DOD applications over past 3 years that preceded this successful one. Learnt a lot from reviewers’ comments. #KeepItReal #LeukemiaResearch @MDAndersonNews
English
13
1
89
6.1K
Ghayas Issa
Ghayas Issa@GhayasIssa·
Menin inhibition is a standard of care! FDA approval of revumenib!! So happy to see that the benefit witnessed in patients on study is leading to a medicine to all who need it. Ready to forj ahead with more to come! ;)
Ghayas Issa tweet media
English
11
38
183
20.7K
Ghayas Issa
Ghayas Issa@GhayasIssa·
The first BTC trial to target AML MRD with combination of menin and BCL2 inhibition is now open! Huge team effort and more exciting trials for MRD to come. Goal is to better measure, understand and treat MRD
𝗕𝗿𝗲𝗮𝗸 𝙏𝙝𝙧𝙤𝙪𝙜𝙝 𝗖𝗮𝗻𝗰𝗲𝗿@break_cancer

We’ve enrolled the first patient in a phase 2 clinical trial targeting minimal residual disease in #AML, hoping to prevent relapse by eliminating lingering cancer cells. #RadicalCollaboration @GhayasIssa @MDAndersonNews

English
4
12
51
7.8K
Elizabeth Ellis MD, MS
Elizabeth Ellis MD, MS@Dr_Liz_Ellis_MD·
I am honored. Thank you @KidneyCancer, @kidneycoa and a special shout out to @kaydaustin who's tireless work spearheading chromophobe RCC should not go unnoticed. Thank you to my outstanding mentors @MDAndersonNews : @PavlosMsaouel , Jose Karam & Niki Zacharias for your support
Kidney Cancer@KidneyCancer

@LauraBukavinaMD @ClevelandClinic 🎉Congratulations @Dr_Liz_Ellis_MD @MDAndersonNews! She received KCA’s #ChRCC Focus Award in partnership with @kidneycoa to identify biomarkers that might indicate if #chromophobeRCC will respond to treatment.

English
3
4
37
4K
Tim Heffernan retweetledi
Only In Boston
Only In Boston@OnlyInBOS·
The Boston Celtics are NBA Champions! The NBA team with the most championship trophies!
Only In Boston tweet media
English
54
2.1K
9K
328.7K
Tim Heffernan retweetledi
Adam Schefter
Adam Schefter@AdamSchefter·
Banner No. 18.
Adam Schefter tweet media
Norsk
210
1.1K
8.7K
710.9K
Tim Heffernan retweetledi
UT MD Anderson
UT MD Anderson@UTMDAnderson·
Thank you to everyone who stopped by our booth at #AACR24 to discuss the latest cancer research advances. We hope to see you all again next year. #EndCancer
UT MD Anderson tweet mediaUT MD Anderson tweet mediaUT MD Anderson tweet mediaUT MD Anderson tweet media
English
1
10
43
7.7K

Keşfet

@ASCO @ACKoongMDPhD @Aiims1742 @rkalluriMDPhD @Boehringer @IamLinghua @cjder23 @broadinstitute